Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
October 2003
Features
A Comparison of Two Macrolide Antibiotics in the Treatment of Community-Acquired Infections
The authors conducted a retrospective study of failure rates and performed a cost-minimization analysis of azithromycin and clarithromycin.
Kavita Parmar-Lapasia, PharmD, Steven P. Gelone, PharmD, Michael R. Jacobs, PharmD, and Albert I. Wertheimer, PhD, MBA
Spotlight
The Changing Role of the Infectious Disease Specialist: A Conversation with Timothy Babinchak, MD
Dr. Babinchak talks about the unexpected turns during his career in the field of infectious diseases.
Sonja Sherritze
Principles of Antibiotic Formulary Selection for P&T Committees, Part 5: The Cost of Antimicrobial Therapy
Dr. Cunha describes some of the cost factors that P&T committees should consider when selecting antibiotics.
Burke A. Cunha, MD
Integrative Medicine in Pharmacy and Therapeutics
Dr. Micozzi provides an overview of the changes taking place in traditional medicine and the new roles of “alternative,” “complementary,” and “holistic” healing practices.
Marc S. Micozzi, MD, PhD
Pharmaceutical-Approval Update: Oncology
Dr. Goldenberg reviews bortezomib for injection (Velcade™) for multiple myeloma, gefitinib (Iressa™) for non-small cell lung cancer, and Bexxar® for non-Hodgkin’s lymphoma.
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
The AMCP’s Drug Dossier Format
David Nash, MD, MBA, discusses the AMCP’s drug dossier format.
David B. Nash, MD, MBA
Prescription Washington
Card Games: Shuffling Ideas to Create a Medicare Discount Drug Card
Stephen Barlas discusses Congressional efforts to create a Medicare discount drug card.
Stephen Barlas
Medication Errors
Reducing Medication Errors Associated with Intravenous Insulin Infusions
Matthew Grissinger explains the potential for errors with intravenous insulin infusions.
Matthew Grissinger, RPh, FASCP
Drug News
New Drugs/Drug News
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA.
Drug Forecast
Gefitinib: The First in a New Class of Agents for Non-Small Cell Lung Cancer
Drs. Ruffin and Harris review gefitinib (Iressa™), a new agent for the treatment of non-small cell lung cancer.
Charnelda G. Ruffin, PharmD, and Kathryn L. Harris, PharmD, MSHCM
